Accuray Incorp Stock Price, News & Analysis

Accuray (NASDAQ: ARAY) announced a leadership and board overhaul to accelerate a company-wide transformation, effective October 20, 2025. Steve La Neve was appointed CEO and Suzanne Winter will retire and remain an advisor through November. Steven F. Mayer was named Transformation Board Sponsor and Chan W. Galbato was nominated to the board.

The company provided preliminary fiscal 2026 Q1 figures: total revenues of $92.5–$94.0 million and adjusted EBITDA of approximately ($4) million. Management said service revenues exceeded plan while product revenues missed expectations in EIMEA and China. The Board targets a high single‑digit adjusted EBITDA margin run‑rate within 12 months and double‑digit margins over the medium to long term.

Accuray (NASDAQ: ARAY) announced that 5D Clinics and JV partner Icon Group treated the first patients in Melbourne using the CyberKnife S7 System on October 8, 2025.

The JV plans to open and operate CyberKnife centers across Australia, initially focusing on the East Coast; alphaXRT is the exclusive distributor and supported installation through first patient treatment. The CyberKnife S7 enables 1–5 outpatient SBRT/SRS sessions versus traditional 30–40 fractions, and the press release cites projected new cancer cases in Australia rising ~50% from 2022 to 2045.

Expansion is noted as subject to Australian regulatory approvals.

Accuray (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health have signed a memorandum of understanding to advance online adaptive radiotherapy (OART) on Accuray's helical radiation treatment platform. The collaboration will focus on clinical research, education and training, and adaptive technology development to enhance cancer care personalization and precision.

The partnership is particularly significant as UW-Madison researchers were the original inventors of the TomoTherapy® System, the first helical radiation delivery platform. The system revolutionized radiation medicine by enabling integrated 3D daily image-guidance with intensity-modulated radiation therapy (IG-IMRT). The collaboration aims to make OART more accessible to clinical departments of all sizes while advancing the technology's capabilities.

Accuray (NASDAQ: ARAY) has launched the Accuray Stellar Solution, an advanced all-in-one radiotherapy platform initially for the U.S. market. The solution integrates with the company's Radixact Treatment Delivery System and includes comprehensive tools for adaptive radiotherapy.

The system offers multiple delivery modalities including IMRT, SBRT, and SGRT, targeting various cancer types such as breast, prostate, lung, and head and neck cancers. Key features include ClearRT helical kVCT imaging, Synchrony technology for real-time motion tracking, PreciseART for offline adaptive protocols, and the new Adapt LTE powered by Accuray Cenos for treatment evaluation and training.

Accuray (NASDAQ: ARAY) announced it will host an analyst and investor event during the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco on September 29, 2025. The hybrid event, starting at 1:30 PM PT, will feature global thought leaders discussing adaptive radiotherapy in radiation medicine.

The presentation will cover key topics including the adaptive radiotherapy spectrum, programmatic vision, practice integration, workflow realities, and motion management from a global perspective. Both in-person and virtual attendees must register by September 25, 2025.

Accuray (NASDAQ: ARAY) reported its Q4 and fiscal 2025 results with mixed performance. Q4 revenue decreased 5% to $127.5 million, while full-year revenue grew 3% to $458.5 million. The company posted Q4 net income of $1.1 million compared to $3.4 million in the prior year, while recording a full-year net loss of $1.6 million, improved from a $15.5 million loss in FY24.

Service revenue showed strength with a 4% increase in both Q4 and full-year results. The company successfully completed a debt refinancing and maintained a book-to-bill ratio of 1.2. For FY26, Accuray projects revenue between $471-485 million and adjusted EBITDA of $31-35 million.

Accuray (NASDAQ: ARAY) has scheduled its fourth quarter fiscal 2025 financial results conference call for August 13, 2025, at 1:30 p.m. PT/4:30 p.m. ET. The company will provide financial results for the quarter ended June 30, 2025.

Investors can access the call through U.S. dial-in (1-888-999-5318) or international dial-in (1-848-280-6460). A replay will be available for one week after the call. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q1 fiscal 2026 results.

Accuray (NASDAQ: ARAY) announced a significant financial restructuring, including the exchange of $82.0 million in convertible notes for 8,881,579 shares of common stock plus $68.6 million in cash. The company secured new credit facilities with TCW Asset Management Company totaling $190 million, comprising a $150 million term loan, $20 million delayed draw facility, and $20 million revolving credit facility. The financing includes the issuance of warrants for approximately 23.4 million shares. As part of the agreement, TCW gains board representation, with Steven F. Mayer joining Accuray's Board of Directors. The new financing structure aims to enhance liquidity and operational flexibility, with proceeds being used to refinance existing debt. Interest rates on the facilities range from SOFR plus 8.50% to base rate plus 7.50%, with partial PIK options.

Accuray (NASDAQ: ARAY), a radiation therapy solutions provider, announces its participation in the Jefferies Global Healthcare Conference 2025. The company's management team will engage in a fireside chat on June 4th, 2025, at 5:30pm EDT/2:30pm PDT. The presentation will be accessible via live webcast through Accuray's Investor Relations website, with replay available for 90 days. Accuray, headquartered in Madison, Wisconsin, specializes in developing innovative radiation therapy solutions for oncology and neuro-radiosurgery, focusing on both complex and routine treatment cases to enhance patient care delivery.